SCHEDULE 13G/A: Investment Funds Disclose Passive 4.55% Stake in 180 Life Sciences Corp.

Ayrton Capital LLC and Alto Opportunity Master Fund, along with Waqas Khatri, have disclosed a passive 4.55% beneficial ownership stake in 180 Life Sciences Corp. through warrants.

Summary

• A Schedule 13G filing indicates that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri (collectively, the "Reporting Persons") have a beneficial ownership interest in 180 Life Sciences Corp.
• Each Reporting Person beneficially owns 247,105 shares of Common Stock of 180 Life Sciences Corp.
• This ownership represents 4.55% of the Issuer's Common Stock class.
• The shares are issuable upon the exercise of certain warrants held by the Reporting Persons.
• The issuable shares are subject to a 9.99% beneficial ownership blocker.
• The percentage of class is calculated based on 5,185,780 shares of Common Stock outstanding as of March 31, 2025, as stated in the Issuer's Form 10-K, plus the 247,105 shares issuable from the warrants.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the Issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing passive beneficial ownership. It does not contain information that would significantly alter the sentiment towards the company, as it's a disclosure of an existing stake via warrants rather than new investment or operational news.

Positives

• The disclosure of a beneficial ownership stake by investment funds like Ayrton Capital LLC and Alto Opportunity Master Fund indicates investor interest in 180 Life Sciences Corp.

Negatives

• No negative aspects related to the company's performance or operations are disclosed in this beneficial ownership filing.

Risks

• None explicitly mentioned in this filing regarding the Issuer's operations or financial health. The document primarily details beneficial ownership.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding the Issuer's future outlook.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine disclosure of passive beneficial ownership and does not provide specific analysis of broader industry trends or competitive landscape for 180 Life Sciences Corp.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory requirement for passive investors acquiring more than 5% but less than 20% of a company's stock, or for certain institutional investors. The 4.55% stake reported here is below the 5% threshold for a new 13G, but this is an amendment (Amendment No. 001), suggesting a previous filing or a change in calculation. The beneficial ownership blocker (9.99%) is a common contractual provision in warrant agreements to prevent immediate triggering of certain ownership thresholds.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant, albeit passive, investor holding warrants convertible into common stock. This indicates continued investor interest.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this beneficial ownership filing, as it does not relate to the company's operations, financial health, or strategic direction.

Next Steps

• No specific future actions, events, or milestones for the Issuer are mentioned in this beneficial ownership filing.

Key Dates

Keywords

180 Life Sciences Corp., Ayrton Capital LLC, Alto Opportunity Master Fund, Waqas Khatri, Schedule 13G, beneficial ownership, common stock, warrants, passive investment, SEC filing